Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that Filippo Petti, CEO of Celyad, is joining the Celyad Board of Directors and succeeds Celyad co-founder and former CEO Christian Homsy, M.D. who has resigned from Celyad’s Board of Directors.

Dr. Christian Homsy steps down from the Celyad Board of Directors as current CEO Filippo Petti is nominated into the role.

“I am proud of and thankful to the Celyad team for what they have accomplished over the years.  I wish them and Filippo the best for the future” said Dr. Homsy.

“I’d like to thank Christian for his guidance and support during the past few months as I’ve transitioned into the role of CEO” said Filippo Petti, CEO of Celyad. “I am honored to accept this appointment to Celyad’s Board of Directors and I look forward to continuing to work closely with the Board to execute on the Company’s strategic vision.”

Michel Lussier, Chairman of Celyad, noted “We thank Christian for all his leadership and dedication since his co-founding of Celyad. His impact on the Company has been tremendous. Though he is leaving our Board, we know he will remain intensely interested in the Company’s future progress towards becoming a leader in the field of CAR-T cell therapy. We are also very pleased to welcome Filippo on the Board”

Download press release(s)

Press release

92.98 Ko

Communiqué de presse

108.93 Ko

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Next News

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding